I’m going to be annoyingly precise up front, because sloppy labels create sloppy conclusions. “GLP-3” gets thrown around online like it’s a normal human gut hormone sitting next to GLP-1 and GLP-2. In mammals, that’s not really a thing. What most people are actually pointing at with “GLP-3” is the recent wave of triple-agonist incretin peptides—engineered drugs designed to co-activate GLP-1 receptor (GLP-1R), GIP receptor (GIPR), and glucagon receptor (GCGR).

So this post is about “GLP-3” in the way the market uses the term: GLP-1/GIP/glucagon tri-agonism. I’ll also note—briefly— the one place where “GLP-3” is a real comparative endocrinology idea (non-mammalian proglucagon products), because that’s part of why the naming confusion persists.

Executive summary (what’s solid vs what’s still squishy)

• “GLP-3” is a sloppy umbrella term. In common usage it usually means tri-agonist peptides (GLP-1R + GIPR + GCGR), not a canonical human hormone.
• The efficacy signal is real. In early human trials, at least one tri-agonist (retatrutide / LY3437943) produced large, dose-dependent weight loss and improved metabolic markers.
• The safety/tolerability constraints are also real. GI adverse events are common and dose-related (class-consistent), and heart-rate increases show up often enough that any serious researcher should treat it as a major unresolved question.
• Organ signals (liver, kidney) are promising but confounded. Weight loss improves a lot of downstream biomarkers. Separating “direct” organ pharmacology from “indirect weight-loss mediation” is where the next round of research needs to be honest.
• Regulatory reality matters. Unapproved GLP-1–class drugs (including compounds being sold as “for research only”) have drawn explicit warnings from regulators; provenance and oversight are not optional if you’re doing legitimate work.

First, the naming problem: what “GLP-3” can mean

1) The comparative endocrinology meaning

There’s a niche literature where additional proglucagon-derived peptides (sometimes labeled “GLP-3”) are discussed in non-mammalian species. That’s interesting academically, but it doesn’t map cleanly onto human incretin pharmacology or clinical use. Treat it like a different branch of biology, not a direct therapeutic blueprint.

2) The thing people usually mean: tri-agonist incretin drugs

The “GLP-3” label gets used as shorthand for triple incretin agonism: one engineered peptide, three receptors: GLP-1R + GIPR + GCGR. The core idea is simple: GLP-1 and GIP drive incretin biology (insulin support, appetite effects), while glucagon signaling adds an energy-expenditure lever—useful for weight loss, but potentially risky for glycemic control if not balanced.

Examples you’ll see in primary sources:

• Retatrutide (LY3437943) — weekly dosing in studies; strong weight-loss signal in obesity trials.
• NN1706 (also described as MAR423 / RO6883746 in different contexts) — daily tri-agonist; includes preclinical + early human work.
• SAR441255 — described as an exendin-4–based tri-agonist with translational receptor-engagement work; program was discontinued.

Mechanism: why three receptors instead of one

If you want a conservative, testable mental model, it’s this: tri-agonists attempt to combine intake suppression (mostly GLP-1R-driven, with GIPR-dependent nuances) with expenditure support (via GCGR), while using incretin signaling to buffer the hyperglycemic liability that glucagon receptor activation can introduce.

Tri-agonist peptide
  ├─ GLP-1R activation → satiety signaling + slower gastric emptying (class-consistent) → ↓ energy intake
  ├─ GIPR activation   → incretin support (context-dependent effects in adipose/CNS are still debated)
  └─ GCGR activation   → ↑ energy expenditure signals (and ↑ hepatic glucose output risk)

Net phenotype depends on potency balance + exposure + tolerability ceiling.
    

The phrase “potency balance” isn’t marketing fluff—GCGR is a sharp instrument. If you dial it too high, you can buy weight loss at the cost of glycemic stability. If you dial it too low, you’re back to “basically a GLP-1–like,” and the tri-agonist claim becomes decorative.

What the data actually show (preclinical + human)

Preclinical: the familiar pattern, plus a recurring hemodynamic flag

In obese rodent models, tri-agonists generally reduce body weight and food intake, and some studies support an energy-expenditure contribution via indirect calorimetry. That’s the “of course it works in mice” part.

The part worth taking seriously is what keeps showing up across programs: heart-rate increases in preclinical telemetry work (notably in non-human primates for some candidates), and the question of whether that’s autonomic, direct receptor biology, or an exposure/time artifact that adapts. If you’re building a research plan, this is not a footnote—it’s a priority.

Human trials: retatrutide is the clearest public dataset

In a phase 2 obesity trial, retatrutide (LY3437943) produced large, dose-dependent weight loss over time, with GI adverse events as the most common tolerability limit and dose-related increases in heart rate reported in supplemental measurements. The direction of blood pressure often moves favorably, but heart rate is the signal that keeps the benefit-risk conversation honest.

Retatrutide also has a phase 2a MASLD (fatty liver disease) substudy using MRI-PDFF, showing large reductions in liver fat. That’s encouraging, but it still leaves open the hard endpoints (histology, fibrosis trajectory) and the mediation question: how much is “direct hepatic biology” versus “weight-loss downstream.”

Renal biomarker analyses (e.g., albuminuria measures like UACR) show improvements in some contexts, but interpretation can be limited when baseline albuminuria is low—nice-looking relative changes can translate into modest absolute clinical impact. Again: interesting signal, not a victory lap.

Safety and tolerability: what a serious reader watches

• GI events (nausea, vomiting, diarrhea, dyspepsia) are common and dose-related—this is the exposure ceiling for many participants.
• Heart rate increases show up repeatedly; mechanism and long-term significance are still being resolved.
• Class monitoring concerns in protocols often include pancreatitis adjudication, gallbladder/biliary events, dehydration-linked renal events, and standardized monitoring for mood/suicidality. These aren’t “guaranteed outcomes,” but they are risks sponsors treat as credible enough to track.

Regulatory reality (because biology doesn’t exist in a vacuum)

Regulators have specifically warned consumers about unapproved GLP-1 drugs sold for weight loss and have addressed the pattern of products being sold illegally while labeled “for research only.” If you’re doing legitimate work, provenance matters: authenticated material, lawful acquisition, appropriate ethics review, and transparent reporting.

Research gaps that actually matter (if you’re not just repeating press releases)

1) Heart-rate mechanism under chronic exposure

Treat the heart-rate signal as a first-class research problem. You want time-resolved telemetry + PK/PD linkage + autonomic markers, not just a single clinic pulse measurement.

2) Weight-loss–independent organ effects

If you want to claim “direct kidney benefit” or “direct liver benefit,” you need designs that can separate direct effects from caloric deficit: pair-feeding controls, mediation models, and ideally receptor-specific perturbations.

3) Receptor contribution and “balance” isn’t a vibe—measure it

In vitro potency/efficacy panels across GLP-1R, GIPR, and GCGR (plus bias/internalization profiles) should be treated as baseline characterization, not optional decoration. Structure papers are useful for hypotheses, but organism-level causality still requires hard controls.

4) Body composition, bone, and functional outcomes

Massive weight loss changes physiology. “Less lean mass loss” is not the same as “no functional risk.” If the field wants to be mature, it needs more muscle function and bone endpoints—especially as these agents push into longer durations and broader populations.

Quick study map (copy/paste friendly)

Primary sources (start here if you want to be dangerous in a good way)

• Retatrutide phase 2 obesity RCT (PMID 37366315): PubMed link
• LY3437943 phase 1b in type 2 diabetes (PMID 36354040): PubMed link
• Retatrutide MASLD substudy (open access on PMC): PMC link
• Retatrutide kidney parameters analysis (ScienceDirect page): Article page
• NN1706 (MAR423) preclinical + first-in-human report (open access on PMC): PMC link
• SAR441255 tri-agonist (Cell Metabolism; PubMed record): PubMed link
• FDA safety communication on unapproved GLP-1 drugs used for weight loss: FDA link
• CONSORT 2010 (trial reporting standard; PMID 20334632): PubMed link
• ARRIVE 2.0 (animal research reporting; open access on PMC): PMC link

Bottom line: “GLP-3” is a meme-term for a real pharmacology strategy. The strategy is powerful, but it isn’t magic—and it’s not “settled science” just because the weight-loss graphs look dramatic. If you want to contribute rather than echo, go after mechanism and safety with designs that can survive a hostile lab meeting.